Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

MLA

Dusica Cvetinovic Santos, et al. “Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.” Journal of Medicinal Chemistry, vol. 62, Aug. 2019, pp. 7643–55. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cb51d59d700ed35c9b5eb75576ca2e2d&authtype=sso&custid=ns315887.

APA

Dusica Cvetinovic Santos, Klaus Urbahns, Simone C. Zimmerli, Andreas Goutopoulos, Justin R. Potnick, Andrew Bender, Michael Meyring, Adam Shutes, Christopher Charles Victor Jones, Jared Head, Ben C. Askew, Bayard R. Huck, Ansgar Wegener, Hui Qiu, Theresa L. Johnson, Nadia Brugger, Sherer Brian A, Ngan Nguyen, Mohanraj Dhanabal, … Thomas Eichhorn. (2019). Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. Journal of Medicinal Chemistry, 62, 7643–7655.

Chicago

Dusica Cvetinovic Santos, Klaus Urbahns, Simone C. Zimmerli, Andreas Goutopoulos, Justin R. Potnick, Andrew Bender, Michael Meyring, et al. 2019. “Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.” Journal of Medicinal Chemistry 62 (August): 7643–55. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cb51d59d700ed35c9b5eb75576ca2e2d&authtype=sso&custid=ns315887.